Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCG | P05129 | 6/20 | 0.64 |
| ▸ | PRKCZ | Q05513 | 6/20 | 0.64 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.64 |
| ▸ | PRKCB | P05771 | 5/20 | 0.64 |
| ▸ | PRKCA | P17252 | 5/20 | 0.64 |
| ▸ | PRKCH | P24723 | 5/20 | 0.64 |
| ▸ | PRKCI | P41743 | 5/20 | 0.64 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.64 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.64 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.64 |
| ▸ | PRKACA | P17612 | 5/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.64 |
| ▸ | PRKACG | P22612 | 4/20 | 0.64 |
| ▸ | PRKACB | P22694 | 4/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7431693 | 0.86 | PRKCG (0.63) | PRKCGPRKCZPRKCDPRKD3PRKCB | |
| SCHEMBL10985713 | 0.84 | PRKD3 (0.60) | PRKCGPRKCZPRKCDPRKD3PRKCB | |
| SCHEMBL10988492 | 0.83 | PRKD3 (0.59) | PRKCGPRKCZPRKCDPRKD3PRKCB | |
| SCHEMBL7435892 | 0.82 | PRKD3 (0.57) | PRKCGPRKCZPRKCDPRKD3PRKCB | |
| SCHEMBL9541267 | 0.81 | PRKD3 (0.61) | PRKCGPRKCZPRKCDPRKD3PRKCB | |
| SCHEMBL10983757 | 0.80 | PRKD3 (0.56) | PRKCGPRKCZPRKCDPRKD3PRKCB | |
| SCHEMBL2117507 | 0.80 | CYP3A4 (0.58) | PRKCGPRKCZPRKCDPRKD3PRKCB | |
| SCHEMBL7481978 | 0.79 | PRKCG (0.68) | PRKCGPRKCZPRKCDPRKD3PRKCB | |
| SCHEMBL1272424 | 0.78 | PRKACA (1.00) | PRKCGPRKCZPRKCDPRKD3PRKCB | |
| SCHEMBL29968125 | 0.78 | PRKACA (1.00) | PRKCGPRKCZPRKCDPRKD3PRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407939-B2 | Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or peptidomimetics | CUREGENICS LTD. (IL) | 2008-08-05 | — | — | US | disclosed |
| EP-1284734-B1 | ISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CUREGENICS LTD (IL) | 2008-05-21 | — | — | EP | disclosed |
| US-20080070843-A1 | PROTEIN KINASE INHIBITORS COMPRISING ATP MIMETICS CONJUGATED TO PEPTIDES OR PEPTIDOMIMETICS | CUREGENICS LTD. | 2008-03-20 | — | — | US | disclosed |
| US-6949565-B2 | Protein kinase inhibitors | DEVELOGEN ISRAEL LTD. (IL) | 2005-09-27 | — | — | US | disclosed |
| US-20050026840-A1 | Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or pertidomimetics | CUREGENICS LTD. (IL) | 2005-02-03 | — | — | US | disclosed |
| EP-1284734-A4 | PROTEIN KINASE INHIBITORS | PEPTOR LTD (IL) | 2004-03-10 | — | — | EP | disclosed |
| US-20040019077-A1 | Heterocyclic imines such as N1-(8-sulfonamide-5-isoquinoline)-N2-(3,3-diphenyl-2-propenyl) -ethylenediamine, used for prophylaxis and diagnosis of cancers, diabetes, cardiovascular and nervous system disorders, autoimmune diseases or obesity | CUREGENICS LTD. (IL) | 2004-01-29 | — | — | US | disclosed |
| EP-1284734-A1 | PROTEIN KINASE INHIBITORS | Peptor Ltd. (IL) | 2003-02-26 | — | — | EP | disclosed |
| WO-2001091754-A1 | PROTEIN KINASE INHIBITORS | PEPTOR LTD. (IL) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070843-A1 | PROTEIN KINASE INHIBITORS COMPRISING ATP MIMETICS CONJUGATED TO PEPTIDES OR PEPTIDOMIMETICS | ADK, PRKCQ, IAPP | PRKCG 39/4885PRKCZ 71/4885PRKCD 176/4885 |
| US-20040019077-A1 | Heterocyclic imines such as N1-(8-sulfonamide-5-isoquinoline)-N2-(3,3-diphenyl-2-propenyl) -ethylenediamine, used for prophylaxis and diagnosis of cancers, diabetes, cardiovascular and nervous system disorders, autoimmune diseases or obesity | CHKB, MAP4K2, PKN2 | PRKCG 330/4885PRKCZ 409/4885PRKCD 577/4885 |
| US-20050026840-A1 | Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or pertidomimetics | PRKCQ, ADK, PRKCH | PRKCG 8/4885PRKCZ 10/4885PRKCD 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.